Related by context. All words. (Click for frequent words.) 70 cortical stimulation therapy 66 riociguat 66 placebo controlled clinical 66 MGd 65 NLX P# 65 clevidipine 65 safinamide 64 vidofludimus 64 phase IIb clinical 64 repetitive transcranial magnetic stimulation 64 medically refractory 64 GPi 64 ADAGIO study 64 ALA PDT 64 schizophrenia CIAS 64 fosbretabulin 64 functional mitral regurgitation 64 transcranial Doppler ultrasound 64 intraventricular 64 CA4P 64 VAPRISOL 64 Levacor TM 64 teriflunomide 64 GRN# 64 optimal dosing regimens 64 stratifying patients 63 CardioFit 63 brivaracetam 63 phase IIa clinical 63 intermittent dosing 63 knee osteoarthritis OA 63 GAMMAGARD 63 VADT 63 NP2 Enkephalin 63 pain palliation 63 cangrelor 63 liver resection 63 Inhaled nitric oxide 63 dexanabinol 63 transcranial magnetic stimulation TMS 63 mGluR2 NAM 63 RSD# oral 63 intramyocardial 63 opioid induced bowel dysfunction 63 autologous bone marrow 63 ReN# 63 EchoCRT 63 choroidal vasculopathy 63 Dr. Fehlings 63 transcranial magnetic stimulation 63 neurogenic 63 STRIDE PD 63 Phase IIB 63 HuMax EGFr 63 SERCA2a 63 PFO closure 63 Brodmann Area 63 reinnervation 63 cardiac perfusion 63 intra arterial 63 thoracoscopic lobectomy 63 vernakalant hydrochloride 62 Catena ® 62 randomized blinded 62 recurrent glioblastoma 62 cardiac repolarization 62 Vernakalant 62 ablation procedures 62 recurrent glioblastoma multiforme 62 EDEMA3 trial 62 Pimavanserin 62 thetreatment 62 PFO migraine 62 Lixivaptan 62 cannabinor 62 visilizumab 62 ziconotide 62 Fontan procedure 62 mTOR inhibition 62 QT QTc 62 myocardial revascularization 62 somatostatin analog 62 spinal cord stimulation 62 Rheos System 62 ExTRACT TIMI 62 phase IIb trial 62 Pharmacokinetic studies 62 cediranib 62 antiarrhythmic drug 62 remyelination 62 PRIMO CABG 62 immunomodulatory therapy 62 COMT inhibitors 62 Proxinium TM 62 tDCS 62 photocoagulation 62 CARE HF 62 EVIZON 62 Xanafide 62 lenalidomide dexamethasone 62 QTc prolongation 62 NeuroFlo 62 BioSTAR R 62 occlusive disease 62 ProSavin 62 PhG alpha 1 62 CBLC# 61 pertuzumab 61 iroxanadine 61 SYN# 61 chronic myocardial ischemia 61 trodusquemine 61 esophagogastric 61 Provacel 61 ablative therapy 61 edifoligide 61 cilengitide 61 thalidomide Thalomid 61 Perceiva 61 NATRECOR R 61 Phase IIb III 61 SpyGlass System 61 lomitapide 61 Amplimexon 61 AGHD 61 Phase IIb clinical trials 61 multicenter Phase II 61 MIST II 61 dexpramipexole 61 phase IIIb 61 Phase Ib study 61 imexon 61 double blinded placebo 61 electrocardiography ECG 61 QTinno TM 61 antiangiogenic therapy 61 REG1 61 Teriflunomide 61 valve implantation 61 Enkephalin 61 ONCONASE R 61 refractory angina 61 Zybrestat 61 pharmacodynamic endpoints 61 agomelatine 61 Zevalin consolidation 61 MP4OX 61 EP #R 61 Revimmune 61 MEND CABG 61 factor Xa inhibitor 61 Subgroup analysis 61 Viprinex 61 nonrandomized 61 PICSO ® 61 bi ventricular pacing 61 ACTEMRA TM 61 icatibant 61 Phase Ib clinical 61 midstage clinical 61 Urocortin 2 61 pouchitis 61 OncoGel 61 zotarolimus 61 magnetic stimulation 61 transfemoral 61 PDE4 inhibitor 61 symptomatic paroxysmal AF 61 neurotrophic 61 Capesaris 61 DACH platinum 61 Tasimelteon 61 relapsing multiple sclerosis 61 subconjunctival injection 61 rotary VAD 61 Phase III metastatic melanoma 61 Levacor 61 QuadraSphere 61 intracoronary 61 ELACYT 61 neuroprotection 61 BRIM2 61 nab paclitaxel 61 chronic thromboembolic pulmonary 61 CIMZIA ™ 61 perfusion defects 61 tasimelteon 61 enzastaurin 61 Degarelix 61 chemoradiotherapy 61 Desmoteplase 61 comparator arm 61 fallopian tube cancers 60 rTMS 60 levodopa induced 60 CoAxia 60 ZACTIMA 60 AGILECT R 60 electrophysiologic 60 secretin 60 Ophena 60 SomatoKine 60 electroencephalographic 60 rindopepimut 60 ZFP TF 60 antiangiogenic 60 somatosensory evoked potentials 60 pediatric malignancies 60 RRMS patients 60 haematological cancers 60 analgesic efficacy 60 Pyridorin 60 decitabine 60 TMS Therapy 60 opioid analgesia 60 phase IIb study 60 plaque excision 60 Factor VIIa 60 OvaRex MAb 60 Valdoxan 60 uricase 60 prospective multicenter 60 MAGE A3 ASCI 60 neurostimulation 60 rufinamide 60 NOX E# 60 Lu AA# 60 vivo validation 60 Safinamide 60 sd rxRNA 60 ruboxistaurin 60 transapical 60 HGS# 60 CA9 SCAN 60 miglustat 60 vorinostat 60 HeartNet 60 transcranial Doppler 60 sitaxsentan 60 forodesine 60 tolvaptan 60 concurrent chemoradiation 60 endoluminal 60 terlipressin 60 EFAPROXYN 60 PAOD 60 neovascular 60 aerosolized KL4 surfactant 60 treprostinil 60 subthalamic nucleus STN 60 antiarrhythmic 60 cartilage regeneration 60 diagnostic biomarker 60 TG# [003] 60 F FDG PET 60 edifoligide E2F Decoy 60 rBChE 60 BrachySil TM 60 BoNTA 60 cardioembolic stroke 60 triphendiol 60 clinically meaningful improvement 60 ACZ# 60 velafermin 60 renal artery stenting 60 Catheter ablation 60 plasma kallikrein inhibitor 60 small molecule activators 60 thorough QT 60 pharmacokinetic PK 60 anti angiogenic agents 60 functional electrical stimulation 60 DDP# 60 EEG biofeedback 60 SNT MC# 60 ganaxolone 60 flurpiridaz F 60 hypervascular tumors 60 Phase #b/#a trial 60 rALLy clinical trial 60 intravenous cyclophosphamide 60 inhaled AAT 60 synthetic retinoid 60 transthoracic 60 Vilazodone 60 biliary tract cancer 60 active comparator 60 gemcitabine Gemzar ® 60 favorable pharmacokinetic profile 60 antibody MAb 60 paricalcitol 60 Telintra 60 CompuFlo 60 Dacogen decitabine 60 pharmacologic therapies 60 EXPAREL 60 EnRhythm MRI SureScan pacing 60 Prestara 60 colorectal cancer liver metastases 60 nonmetastatic prostate cancer 60 mertansine 60 Carotid Revascularization Endarterectomy vs. 60 GEM OS1 60 Squalamine 60 atacicept 60 midstage clinical trials 60 ZOLINZA 60 topical formulation 60 dopaminergic therapy 59 ibudilast 59 canakinumab 59 Cimzia TM 59 beta 1a 59 TYSABRI natalizumab 59 ConclusionThis 59 gefitinib Iressa 59 neurosensory 59 NOD mouse 59 YONDELIS 59 kidney urologic 59 platelet inhibitor 59 clinical pharmacology studies 59 pharmacologic 59 Chrysalin 59 Plicera 59 GED aPC 59 ibandronate 59 fibrotic disease 59 randomized Phase IIb 59 NTx TM -# 59 sargramostim 59 renoprotective 59 lanreotide 59 enhanced external counterpulsation 59 reteplase 59 PD LID 59 prospective randomized multicenter 59 EXPAREL TM 59 tecarfarin 59 intravenous methylnaltrexone 59 JAK inhibitors 59 olmesartan 59 epidural steroid injection 59 CIMZIA TM 59 idiopathic Parkinson disease 59 BGC# 59 MEND CABG II 59 GGF2 59 varespladib 59 ancrod 59 myoblast 59 TLK# 59 dissolving blood clots 59 desmoteplase 59 p# inhibitor 59 NMDA antagonist 59 rFVIIa 59 oral anticoagulation 59 noninfectious uveitis 59 NEVO ™ 59 Vascugel ® 59 ECASS 59 RSD# 59 electrophysiological 59 unstable angina UA 59 gallium nitrate 59 RezularTM 59 pulmonary artery banding 59 CRVO 59 treat benign prostatic 59 pharmacodynamic PD 59 tramiprosate 59 Alocrest 59 ximelagatran 59 MYDICAR ® 59 goserelin 59 alagebrium 59 anterior temporal 59 inotropic 59 inhibiting mTOR 59 EndoTAGTM 1 59 experimentally induced 59 bronchoscopic 59 preclinically 59 IL# PE#QQR 59 nonhuman primate model 59 myogenic 59 clinically meaningful improvements 59 TACI Ig 59 Phase #b/#a 59 zalutumumab 59 VA# [002] 59 abacavir Ziagen 59 generation purine nucleoside 59 eniluracil 59 metreleptin 59 colorectal liver metastases 59 antithrombotic therapy 59 radiation sensitizer 59 Archexin 59 intracranial stenosis 59 ospemifene 59 topical formulations 59 Symadex 59 PROCHYMAL 59 haematologic 59 somatostatin analogue 59 ulimorelin 59 glufosfamide 59 antithrombotic 59 cardiac resynchronisation therapy 59 neovascularisation 59 NV1FGF 59 Imprime PGG 59 desvenlafaxine succinate 59 phase IIa 59 OMS# 59 postoperative ileus POI 59 Enzyme Replacement Therapy 59 pretargeting 59 DAPT 59 Phase 2b study 59 p# biomarker 59 prospective multicenter study 59 ADVEXIN therapy 59 TNF alpha inhibitor 59 BrachySil ™ 59 RhuDex ® 59 cardiac dysfunction 59 RhuDex 59 hyperalgesia 59 ABVD 59 thrombolytic agents 59 basal bolus regimen 59 LB# [003] 59 renal denervation 59 Hepatocellular Carcinoma HCC 59 efficacy endpoint 59 electrostimulation 59 eTag assays 59 OHR/AVR# 59 Azedra 59 Zemiva 59 Anavex #-# 59 choroidal neovascularization 59 neratinib 59 anti fibrotic 59 clot retrieval 59 TTF Therapy 59 HDL Selective Delipidation 59 decompressive surgery 59 CERE 59 mTOR inhibitors 59 Androxal TM 59 cardiac resynchronization 59 placebo controlled Phase III 59 pyridostigmine 59 radiolabeled TM# 59 TASQ 59 Phase IIb trials 59 regorafenib 59 Zilver PTX stent 59 Tyrima 59 hemiplegic 59 Bicifadine 59 drug eluting stent DES 59 Insulin PH# 59 postsurgical pain 59 oral anticoagulant 59 VBLOC Therapy 59 Gattex 59 erythropoietic 59 investigational therapies 59 hypofractionated 59 poststroke 59 MDCT angiography 59 Brinavess 59 Stabilimax NZ 59 Lymphoseek ® 59 elacytarabine 59 CIPN 59 lesional 59 tocilizumab 59 romidepsin 59 EXJADE 59 pharmacokinetic PK study 59 bardoxolone methyl 59 Gabapentin GR 59 targeted radiotherapeutic 59 preclinical efficacy 59 ischemic preconditioning 59 neurologic progression 59 VITAL Trial 59 mGluR2 59 paclitaxel poliglumex 59 cerebral vasospasm 59 PROactive study 59 Phase Ib II 59 CHAMPION PCI 58 neuroregenerative 58 #beta HSD1 58 OPCAB 58 tiapamil 58 anti arrhythmic drug 58 thrombus aspiration 58 inhibitor RG# 58 Thrombolysis 58 Panzem R NCD 58 hyperphenylalaninemia HPA due 58 Fenretinide 58 Spheramine 58 NATRECOR ® 58 Traficet EN 58 elotuzumab 58 Triapine R 58 ATL# [002] 58 CINTREDEKIN BESUDOTOX 58 GORE TAG Device 58 constipation predominant IBS 58 verteporfin 58 randomized Phase 2b 58 farletuzumab 58 zileuton 58 SPECT imaging 58 CRLX# 58 liposomal formulation 58 indibulin 58 atrial arrhythmias 58 multicenter clinical trials 58 Temsirolimus 58 bortezomib Velcade 58 lupus nephritis 58 AeroLEF TM 58 Phase IIIB IV 58 adrenalectomy 58 myocardial ischemia 58 BARI 2D 58 synaptic function 58 Thal Dex 58 prospective longitudinal 58 pharmacodynamic effects 58 antihypertensive therapy 58 latanoprost 58 stellate ganglion block 58 pagoclone 58 resynchronization therapy 58 axillary lymph node dissection 58 tissue oxygenation 58 reslizumab 58 Phase 1a clinical 58 everolimus eluting stents 58 DU #b 58 interferon ribavirin 58 corifollitropin alfa 58 CYT# potent vascular disrupting 58 IRX 2 58 morphometric vertebral fractures 58 full thickness plication 58 myocardial perfusion 58 clinical endpoints 58 cytogenetic abnormalities 58 ATL# [001] 58 Aplidin 58 alvespimycin 58 cystinosis patients 58 Revascor TM 58 Microplasmin 58 Corus CAD 58 PRT# 58 prospective randomized placebo 58 adecatumumab 58 genomic biomarker 58 fenretinide 58 PRX# 58 confirmatory clinical 58 prognostic indicators 58 acetonide FA 58 bucindolol 58 biventricular 58 endothelin antagonists 58 DEEP AF 58 XmAb# 58 intravenous immunoglobulin IVIg 58 IMA# 58 unoprostone isopropyl 58 Edwards SAPIEN valve 58 Virulizin ® 58 hereditary deficiency 58 recurrent malignant glioma 58 Tolvaptan 58 IPL# 58 Zemplar Capsules 58 SEPET TM 58 percutaneous catheter 58 prospectively defined 58 triamcinolone 58 HQK 58 C1 INH 58 cranial radiation 58 proliferative retinopathy 58 Phase 2a clinical trials 58 ataluren 58 arthrography 58 osteoporotic vertebral compression fractures 58 cardioprotection 58 pivotal bioequivalence 58 GMX# 58 PXD# 58 metastatic malignant 58 CTEPH 58 Acute Coronary Syndromes ACS 58 Facet Solutions 58 inhaled treprostinil 58 Instanyl 58 arteriography 58 pamidronate 58 liver metastasis 58 transurethral 58 ocular hypertension 58 BRAF inhibitor 58 NMES 58 bioartificial liver 58 omega interferon 58 symptomatic VTE 58 Aflibercept 58 Cannabinor 58 acadesine 58 HuLuc# 58 graft patency 58 recombinant tissue plasminogen 58 PEMF 58 isoform selective 58 AZOR 58 Dyloject TM 58 PSMA ADC 58 MKC# MKC# PP 58 pharmacodynamic profile 58 pharmacokinetic PK profile 58 receptor tyrosine kinase inhibitor 58 GW# [003] 58 biventricular pacing 58 neuropsychological assessment 58 extracranial 58 immune modulating 58 Phase III randomized controlled 58 mGluR2 positive 58 endoscopic resection 58 RLY# 58 Orqis Medical 58 generalized seizures 58 AF ablation 58 nerve conduction velocity 58 bioabsorbable stent 58 blinded randomized 58 ERCP 58 Src inhibitors 58 urodynamic 58 GRNCM1 58 CaM kinase II 58 migraine prophylaxis 58 multicenter trials 58 urocortin 2 58 volociximab 58 neurostimulator 58 Certolizumab pegol 58 Tryton stent 58 mGluR5 inhibition 58 Trandolapril 58 diagnostic modality 58 colorectal adenoma 58 neuronal signaling 58 RE LY ® 58 Resten NG 58 PDE# inhibitors 58 TriRima 58 pacemaker implantation 58 plasminogen activators 58 pro angiogenic 58 MarginProbe 58 bioengineered tissue 58 methylnaltrexone 58 Cymbalta duloxetine HCl 58 BAY #-# 58 DuraHeart 58 primary hyperparathyroidism 58 NTDDS 58 EDEMA3 58 elective PCI 58 antiangiogenic agent 58 neurostimulation therapy 58 vagus nerve stimulation 58 prostate cancer PCa 58 prognostic variables 58 transarterial 58 Campath alemtuzumab 58 Proellex TM 58 myoblast therapy 58 bevacizumab Avastin ® 58 dose escalation phase 58 Octreolin 58 thoracoscopic 58 recanalization 58 CB1 antagonists 58 intravenous dosing 58 diabetic neuropathic pain 58 dosimetric 58 prognostic biomarker 58 ADVANCE PD 58 CytoFab ™ 58 OZURDEX ® 58 hepatic fibrosis 58 placebo controlled Phase 58 DepoBupivacaine 58 deforolimus 58 oral rivaroxaban 58 CardioPET 58 vagal nerve stimulation 58 neuromotor 58 bolus dose 58 superficial femoral 58 multikinase inhibitor 58 levodopa therapy 58 retinal vein occlusion 58 brain stimulation DBS 58 cleavable linker 58 coronary stenting 58 multicenter randomized placebo controlled 58 Insegia 58 6R BH4 58 Arikace 58 Revlimid lenalidomide 58 flecainide 58 IIa trials 58 STX# 58 Phase IIa trials 58 gonadotropin releasing hormone GnRH 58 amyloid pathology 58 mGluR5 antagonist 58 eosinophilic asthma 58 IFN beta 58 milrinone 58 CURE AF 58 vastus lateralis 58 Cethrin 58 octreotide 58 BrainGate System 58 transesophageal echocardiography TEE 58 retinal vein occlusion induced 58 anticlotting drugs 58 thromboembolic disease 58 chemosensitivity 58 acute mania 58 tenecteplase 58 Zoraxel 58 modified REGENESIS Phase IIb 58 PTHrP 58 biologic therapy 58 atrioventricular block 58 cerebral ischemia 58 prostate cancer CaP 58 viral kinetics 58 intravascular 58 Trophos 58 collagenase 58 Elocalcitol 57 coadministration 57 recurrent GBM 57 rhIGF-I/rhIGFBP-3 57 microbubble 57 AZILECT R 57 stenoses 57 Alequel 57 GEM OS2 57 preclinical pharmacokinetic 57 eculizumab therapy 57 Randomised controlled trials 57 Interferon beta 57 Combo Stent 57 radiotherapy RT 57 hypoperfusion 57 cardiac troponin 57 tumor histology 57 Anturol TM 57 Dupuytren Contracture 57 ASCT 57 Neuradiab 57 neurogenic bladder 57 Cloretazine 57 AGILECT ® 57 Huntexil 57 visuomotor 57 Thorough QT 57 ruxolitinib 57 Fludara ® 57 PHX# 57 axonal regeneration 57 CB2 receptor 57 bioresorbable stent 57 urothelial cancer 57 neurotrophic factor 57 pomalidomide 57 Study #CL# 57 Acute Ischemic Stroke 57 EGFR TKI 57 Phase 2a clinical 57 Randomized Evaluation 57 phase IIb 57 warfarin therapy 57 M6G 57 Carotid endarterectomy 57 BEMA TM Fentanyl 57 anticholinergic agents 57 budesonide foam 57 optimal dosing 57 XP #L 57 vaginally administered lidocaine 57 benign prostatic hypertrophy BPH 57 LVRS 57 CAPHOSOL 57 weekly subcutaneous injections 57 Onconase 57 subcutaneous implant 57 cytoreductive surgery 57 dextofisopam 57 TACE 57 Ceflatonin 57 hemodynamic instability 57 OMNARIS HFA 57 CINQUIL 57 baroreflex 57 prospectively randomized 57 APEX AMI trial 57 ESBA# 57 Phase 2a trial 57 neuropathologic 57 erlotinib Tarceva 57 FDG PET imaging 57 DITPA 57 haemodynamic 57 artery stenosis 57 prodromal symptoms 57 rituximab Rituxan 57 Tavocept 57 idraparinux 57 sonographically guided 57 florbetaben 57 obatoclax 57 Novo TTF 57 Bezielle 57 potent antiproliferative 57 CytoFabTM 57 Aggrastat ® tirofiban hydrochloride 57 PREVENT IV 57 Mitoxantrone 57 Kaplan Meier analysis 57 perfusion imaging 57 Afib 57 Isolagen Therapy 57 Vidaza azacitidine 57 zotarolimus eluting stent 57 myocardial reperfusion 57 claudication 57 novel oral anticoagulant 57 MERLIN TIMI 57 Rasagiline 57 ARIKACE ™ 57 deferiprone 57 abiraterone acetate 57 Selective Electrochemical Tumor Ablation 57 prospective randomized controlled 57 denervation 57 AKT inhibitor 57 LUMINATE 57 EGS# 57 Genz # 57 prospective multicenter randomized 57 trastuzumab Herceptin ® 57 teriparatide 57 NuroPro PD 57 aortic root replacement 57 Xerecept 57 Ascendra 57 CIMZIA TM certolizumab pegol 57 pharmacotherapies 57 TAXUS Liberté stent 57 HIF PH inhibitors 57 Edge STudy 57 ENDEAVOR IV 57 Torisel 57 mechanical thrombectomy 57 femoral neck fracture 57 nadolol 57 anti angiogenic therapy 57 TH# [003] 57 CGRP 57 ENMD # 57 immunomodulatory agents 57 dosage regimens 57 MBCT 57 ASPIRE HIGHER 57 interferon beta therapy 57 BioSTAR ® 57 Relivar 57 phase Ib 57 JAK inhibitor 57 coronary bypass grafting 57 immunotherapeutic vaccine 57 beta secretase inhibitors 57 ZYBRESTAT 57 thromboembolic events 57 subcutaneous SC 57 sorafenib Nexavar 57 oral mTOR inhibitor 57 pharmacodynamic properties 57 NNR Therapeutics 57 BrainCells 57 Phase IIa trial 57 Tamibarotene 57 FFNS 57 stereotactic radiotherapy 57 Tasigna prolongs 57 adipiplon 57 bosentan 57 uric acid lowering 57 SGLT2 inhibitors 57 narrow QRS 57 ISF# 57 ATACAND 57 lapatinib Tykerb 57 PCI ExTRACT TIMI 57 eptifibatide 57 Zenvia ™ 57 antipsychotic efficacy 57 balloon dilation 57 Litx 57 Abciximab 57 CRT ICD 57 dose escalation Phase 57 HepaMate 57 pharmacologic agents 57 transesophageal echocardiography 57 anterior temporal lobe 57 genotypic resistance 57 Ataluren 57 reperfusion therapy 57 CRMD# 57 antioxidant supplementation 57 ACOMPLIA R 57 Nuvion 57 tezampanel 57 cilostazol 57 CALGB # [002] 57 GLYX 57 oncologic outcomes 57 GeneICE 57 multicenter randomized controlled 57 allogeneic stem cell 57 methacholine challenge 57 OmniWave 57 Electroencephalography 57 stereotactic radiation 57 MoxDuo 57 VFEND 57 trospium 57 VBLOC TM 57 biologic DMARD 57 contrast echocardiography 57 hyperoxaluria 57 relapsed MM 57 ABSORB trial 57 receptor inhibitor 57 Troxatyl 57 INCB# [003] 57 molecular biomarkers 57 DP b# 57 hemodynamic variables 57 prospective multicentre 57 Vaprisol 57 ularitide 57 neovascularization 57 vasospasm 57 GBA mutations 57 SGS# 57 hypothalamic pituitary adrenal axis 57 TUMT 57 variceal bleeding 57 radiochemotherapy 57 aplindore 57 Frozen Shoulder Syndrome 57 pulmonary hypertension PH 57 CHARISMA trial 57 axon regeneration 57 GnRH antagonists 57 Orazol 57 Cleviprex TM clevidipine 57 insulin sensitizing 57 PET tracers 57 GLPG# 57 clinically meaningful reductions